Study Of The Expression Of The DLC-1 In Myelodysplastic Syndromes And Its Clinical Implication

ObjectiveTo detect the expression of deleted in liver cancer-1(DLC-1) in the patients with myelodysplastic syndrome(MDS) and its clinical implication. MethodSamples were collected from patients with myelodysplastic syndrome from January to October in 2010, diagnosis according to the WHO classification. Thirty patients and ten controls were investigated: aging from 25 to 79, the median is 56 years old, including MDS-RCMD(4), MDS-RA(8), MDS-RAEB-1(4) and MDS-RAEB-2(14) in MDS group. MDS patients were divided into 3 groups( high-risk,intermediate-risk and low-risk)according to IPSS classification. The relative expression levels of DLC-1 were detected by real time quantitative PCR and analyzed by SPSS 13.0.ResultDLC-1 was expressed in all 30 patients and 10 controls. The△Ct in MDS was 20.11±3.80,significantly higher than that of control group(10.23±2.40)(P<0.05).There was significant difference in the three groups (p<0.05): low-risk group(15.29±2.58), intermediate-risk group(18.61±1.01), high-risk group(23.17±1.97).There was no difference in the four groups (RA,RCMD,RAEB-1,RAEB-2), P >0.05.Conclusion1 The DLC-1 expression levels were significantly lower in MDS patients than that of control group(P<0.05).2 The expression of DLC-1 gene may correlate with the prognosis of MDS.